Virtual discovery of melatonin receptor ligands to modulate circadian rhythms
暂无分享,去创建一个
John D. McCorvy | Bryan L. Roth | Brian K. Shoichet | John J. Irwin | Vadim Cherezov | Olena Savych | Yurii S. Moroz | Terry Kenakin | Tao Che | Samuel T. Slocum | Reed M. Stein | M. Dubocovich | J. Irwin | B. Shoichet | Xi-Ping Huang | B. Roth | T. Kenakin | V. Cherezov | T. Che | L. Johansson | J. McCorvy | B. Stauch | Xi-Ping Huang | Benjamin Stauch | Margarita L. Dubocovich | Hye Jin Kang | Grant C. Glatfelter | Anthony J. Jones | Samuel Slocum | Linda C. Johansson | H. Kang | Olena V. Savych | G. Glatfelter | A. Jones
[1] M. Dubocovich,et al. Melatonin and Light Induce Phase Shifts of Circadian Activity Rhythms in the C3H/HeN Mouse , 1996, Journal of biological rhythms.
[2] U. Singh,et al. A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS , 1984 .
[3] D. Zlotos,et al. Novel difluoroacetamide analogues of agomelatine and melatonin: probing the melatonin receptors for MT1 selectivity , 2015 .
[4] Brian K. Shoichet,et al. Ligand Pose and Orientational Sampling in Molecular Docking , 2013, PloS one.
[5] Joanna L. Sharman,et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..
[6] Hualiang Jiang,et al. Structural insights into lipid and ligand regulation of serotonin receptors , 2019, Nature.
[7] Reid H. J. Olsen,et al. XFEL structures of the human MT2 melatonin receptor reveal basis of subtype selectivity , 2019, Nature.
[8] Reid H. J. Olsen,et al. Structural insights into lipid and ligand regulation of serotonin receptors , 2019, Nature.
[9] M. Gillette,et al. Signaling in the suprachiasmatic nucleus: selectively responsive and integrative , 2002, Cell and Tissue Research.
[10] Brian K. Shoichet,et al. Rapid Context-Dependent Ligand Desolvation in Molecular Docking , 2010, J. Chem. Inf. Model..
[11] M. Dubocovich,et al. Familial advanced sleep phase syndrome. , 2001, Archives of neurology.
[12] R. Stevens,et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.
[13] Maria F. Sassano,et al. PRESTO-TANGO: an open-source resource for interrogation of the druggable human GPCR-ome , 2015, Nature Structural &Molecular Biology.
[14] Jonathan S. Mason,et al. Structures of G protein-coupled receptors reveal new opportunities for drug discovery. , 2015, Drug discovery today.
[15] M. Dubocovich,et al. Carbamate Insecticides Target Human Melatonin Receptors. , 2017, Chemical research in toxicology.
[16] M. Dubocovich,et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors , 2010, Pharmacological Reviews.
[17] M. Dubocovich,et al. Update on melatonin receptors: IUPHAR Review 20 , 2016, British journal of pharmacology.
[18] K. Sharp,et al. Electrostatic contributions to heat capacity changes of DNA-ligand binding. , 1998, Biophysical journal.
[19] Reid H. J. Olsen,et al. XFEL crystal structure of human melatonin receptor MT2 (H208A) in complex with 2-phenylmelatonin , 2019 .
[20] M. Dubocovich,et al. Constitutively active melatonin MT(1) receptors in male rat caudal arteries. , 2002, European journal of pharmacology.
[21] Terry Kenakin,et al. Biased Receptor Signaling in Drug Discovery , 2019, Pharmacological Reviews.
[22] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[23] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[24] Maria F. Sassano,et al. Automated design of ligands to polypharmacological profiles , 2012, Nature.
[25] John J. Irwin,et al. ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..
[26] M. Dubocovich,et al. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. , 2005, Sleep.
[27] Christopher Browning,et al. Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors , 2000, British journal of pharmacology.
[28] J. Emens,et al. The phase shift hypothesis for the circadian component of winter depression , 2007, Dialogues in clinical neuroscience.
[29] P. Zee,et al. Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters , 1997, Brain Research.
[30] Dahlia R. Weiss,et al. Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets , 2018, Journal of medicinal chemistry.
[31] M. Dubocovich. Melatonin receptors: role on sleep and circadian rhythm regulation. , 2007, Sleep medicine.
[32] J. Richardson,et al. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. , 1999, Journal of molecular biology.
[33] C. M. Singer,et al. The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. , 1998, Chronobiology international.
[34] J. Irwin,et al. Docking Screens for Novel Ligands Conferring New Biology. , 2016, Journal of medicinal chemistry.
[35] Xin Chen,et al. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65 , 2015, Nature.
[36] N. Zisapel. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation , 2018, British journal of pharmacology.
[37] Ruben Abagyan,et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.
[38] Jing Liu,et al. In silico design of novel probes for the atypical opioid receptor MRGPRX2 , 2016, Nature chemical biology.
[39] C. Eastman,et al. Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. , 2010, The Journal of clinical endocrinology and metabolism.
[40] M. Dubocovich,et al. Luzindole (N-0774): a novel melatonin receptor antagonist. , 1988, The Journal of pharmacology and experimental therapeutics.
[41] M. Dubocovich,et al. The antidepressant‐like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors , 2005, Journal of pineal research.
[42] M. Polymeropoulos,et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials , 2009, The Lancet.
[43] M. Dubocovich,et al. Selective MT2 melatonin receptor antagonists block melatonin‐mediated phase advances of circadian rhythms , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[44] Nathan Robertson,et al. Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .
[45] M. Caron,et al. Regulation of beta-adrenergic receptors by guanyl-5'-yl imidodiphosphate and other purine nucleotides. , 1976, The Journal of biological chemistry.
[46] Béla Noszál,et al. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. , 2008, Journal of medicinal chemistry.
[47] Yvonne C. Martin,et al. Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..
[48] M. Mor,et al. Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide: synthesis, binding affinity and intrinsic activity for MT(1) and MT(2) melatonin receptors. , 2011, Bioorganic & medicinal chemistry.
[49] Henry Lin,et al. Structure-based discovery of opioid analgesics with reduced side effects , 2016, Nature.
[50] Yurii S. Moroz,et al. Ultra-large library docking for discovering new chemotypes , 2019, Nature.
[51] Min-Sung Kim,et al. Transient mammalian cell transfection with polyethylenimine (PEI). , 2013, Methods in enzymology.
[52] M. Dubocovich,et al. Effect of MT1 melatonin receptor deletion on melatonin‐mediated phase shift of circadian rhythms in the C57BL/6 mouse , 2005, Journal of pineal research.
[53] Jonathan S. Mason,et al. Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.
[54] Arthur Christopoulos,et al. A simple method for quantifying functional selectivity and agonist bias. , 2012, ACS chemical neuroscience.
[55] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[56] J. Boutin,et al. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. , 2003, Journal of medicinal chemistry.
[57] M. Dubocovich,et al. Functional Melatonin Receptors in Rat Ovaries at Various Stages of the Estrous Cycle , 2003, Journal of Pharmacology and Experimental Therapeutics.
[58] M. Dubocovich,et al. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. , 2016, Annual review of pharmacology and toxicology.
[59] T. Handel,et al. What Do Structures Tell Us About Chemokine Receptor Function and Antagonism? , 2017, Annual review of biophysics.
[60] M. Dubocovich,et al. Circadian Periods of Sensitivity for Ramelteon on the onset of Running-wheel Activity and the Peak of Suprachiasmatic Nucleus Neuronal Firing Rhythms in C3H/HeN Mice , 2011, Chronobiology international.
[61] M. Millan,et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development , 2010, Nature Reviews Drug Discovery.
[62] Yurii S Moroz,et al. Expanding Synthesizable Space of Disubstituted 1,2,4-Oxadiazoles. , 2016, ACS combinatorial science.
[63] Harald Hübner,et al. Structure-Guided Screening for Functionally Selective D2 Dopamine Receptor Ligands from a Virtual Chemical Library. , 2017, ACS chemical biology.